DLC1 and renal cell carcinoma: Our group has also identified several novel TSGs silenced by promoter methylation in RCC, including DLC1, DLEC1 and IRF8. The methylation of these TSGs is associated with patient poor prognosis, thus as potential biomarkers for RCC [14–16].